MRK Volume Alert - MRK 58.23 Merck & Company $MRK Hit a high of 58.30 Currently 11:15 Last price 58.23 -1.11 -1.87% With a day low of 57.70 and a current volume of 6,011,049.
MRK Merck & Company Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 52 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.60 (+0.40), GILD: 108.28 (+1.83), ACHN: 12.39 (+2.28), MRK: 58.67 (-0.67), ABBV: 63.82 (+2.32), BMY: 58.55 (+0.23)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 35.71 (-1.22), GOGO: 15.56 (-1.08), GILD: 108.28 (+1.83), MRK: 58.67 (-0.67), CMCM: 20.70 (+0.50), DF: 16.43 (+2.01)
Interim Data from Proof-of-Concept Study of Merck's Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting(R)
Business Wire - Sun Nov 09, 5:53PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Preliminary findings in treatment-naive HCV genotype 1- (GT1) infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting(R).
MRK: 58.67 (-0.67)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 108.28 (+1.83), MRK: 58.67 (-0.67), ABBV: 63.82 (+2.32)
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Nov 07, 10:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is teaming with celebrity chef and cookbook author Leticia Moreinos Schwartz on Desafiando La Diabetes: Logra Tus Metas, an educational program encouraging Hispanics with type 2 diabetes to achieve better control of their blood sugar -- a key treatment goal to help reduce the risk of serious health problems. Hispanics in the United States are at a higher risk for developing type 2 diabetes than non-Hispanic white adults, and it is the fifth leading cause of death within the Hispanic community. Chef Leticia, who has a family history of type 2 diabetes, will visit select cities to cook up some of her favorite diabetes-friendly Latin recipes, urge Hispanics to know their A1C (average blood sugar level over the past two to three months), and work with their doctors to set and attain their own A1C goal.
MRK: 58.67 (-0.67)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 67.26 (+1.51), JNJ: 108.60 (+0.40), PCYC: 133.44 (-0.05), SHPG: 201.52 (+2.94), MRK: 58.67 (-0.67), AMGN: 162.64 (+2.39)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.47 (+0.06), SIAL: 135.60 (+0.26), MRK: 58.67 (-0.67), DHR: 81.38 (+0.19)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.52 (+2.94), PFE: 30.24 (+0.32), MRK: 58.67 (-0.67), AZN: 73.32 (+0.44), TEVA: 58.21 (+0.51), ITCI: 14.92 (-0.34), ABBV: 63.82 (+2.32), BMY: 58.55 (+0.23), OMER: 17.08 (-0.29)
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Thu Nov 06, 12:00PM CST
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a 33-cent decline (-0.6%) bringing the stock to $59.24.
MRK: 58.67 (-0.67)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
Business Wire - Thu Nov 06, 8:08AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA(R) (pembrolizumab) - the company's anti-PD-1 therapy - in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 - 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 - 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 - 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types.
MRK: 58.67 (-0.67)
Stock Futures Shed Losses, Rise; Sierra Wireless, Tableau Rocket
at Investor's Business Daily - Thu Nov 06, 7:58AM CST
Stock futures reversed early losses to point firmly higher ahead of Thursday's open. Dow futures sloughed off a 26-point decline and were up 26.5 points. Nasdaq 100 futures backed out of a 10-point loss to trade 4.2 points above fair market value....
TSLA: 242.08 (+1.88), SWIR: 34.70 (+0.80), V: 250.33 (-2.10), AXP: 92.40 (+0.14), MRK: 58.67 (-0.67), DATA: 83.84 (-1.08), CSCO: 25.10 (-0.23)
BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:30AM CST
--- Strengthened management and Board including Chief Medical Officer -
MRK: 58.67 (-0.67), BIND: 9.21 (-0.01)
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin(TM) Nanomedicines for Oncology
Business Wire - Thu Nov 06, 6:25AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.
MRK: 58.67 (-0.67), BIND: 9.21 (-0.01)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 247.66 (+1.75), LMT: 186.92 (+0.77), XOM: 96.46 (-0.13), ILMN: 189.51 (+3.16), AKS: 6.63 (+0.01), KORS: 69.49 (-0.46), PAYX: 47.54 (+0.21), RIG: 29.43 (-0.28), EOG: 98.98 (-0.57), COST: 137.53 (-0.18), TWTR: 40.00 (-0.31), OXY: 87.87 (-0.17), KO: 42.41 (+0.09), SEAS: 18.53 (+0.14), TMO: 117.06 (+0.46), NUE: 53.74 (-0.44), TRIP: 73.26 (-0.39), DISCA: 32.51 (-0.11), CHUY: 23.04 (+1.02), LB: 76.09 (+0.48), GEO: 41.18 (-0.22), ESV: 40.18 (-1.13), MPC: 93.94 (-0.14), BAX: 70.62 (+0.01), MRK: 58.67 (-0.67), EXPE: 86.10 (+0.99), STI: 39.74 (+0.08)
SANS Institute Announces Healthcare Cyber Security Summit Speaker Line-Up
PR Newswire - Wed Nov 05, 10:02AM CST
The SANS Institute today announced the speaker line-up for its second annual Healthcare Cyber Security Summit in San Francisco on December 3rd. Included among the speaker list are security experts from Aetna, Kaiser Permanente, Merck and Phoenix Children's Hospital.
MRK: 58.67 (-0.67)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 58.68 (-0.66), SHPG: 201.52 (+2.94)
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
Business Wire - Wed Nov 05, 7:30AM CST
--Final stage to focus on planned in-field use studies
MRK: 58.68 (-0.66)
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
GlobeNewswire - Wed Nov 05, 6:46AM CST
Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS31-142 for the treatment of metastatic castration resistant prostate cancer (mCRPC). ADXS31-142 is Advaxis's lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA).
ADXS: 2.86 (+0.11), MRK: 58.68 (-0.66)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 247.66 (+1.75), ECYT: 5.87 (-0.16), MRK: 58.68 (-0.66), HSP: 56.25 (-0.07)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 58.68 (-0.66)
MRK Merck & Company Recent Headline News
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - 52 mins ago
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.60 (+0.40), GILD: 108.28 (+1.83), ACHN: 12.39 (+2.28), MRK: 58.67 (-0.67), ABBV: 63.82 (+2.32), BMY: 58.55 (+0.23)
Premarket: Stock Futures Mixed; Gilead Climbs On Merck News
at Investor's Business Daily - Mon Nov 10, 7:59AM CST
Stock futures shifted from thin, early losses to mixed trade ahead of Monday's open. Nasdaq 100 futures shed losses and were up a narrow 3.5 points. Dow futures remained 2.9 points below fair market value. S&P 500 futures were flat. The stock market...
WWAV: 35.71 (-1.22), GOGO: 15.56 (-1.08), GILD: 108.28 (+1.83), MRK: 58.67 (-0.67), CMCM: 20.70 (+0.50), DF: 16.43 (+2.01)
Interim Data from Proof-of-Concept Study of Merck's Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting(R)
Business Wire - Sun Nov 09, 5:53PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir (MK-5172/MK-8742, MK-5172A), the company's investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide (NS5B) inhibitor for the treatment of chronic hepatitis C virus (HCV) infection. Preliminary findings in treatment-naive HCV genotype 1- (GT1) infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases (AASLD) Annual Meeting, also known as The Liver Meeting(R).
MRK: 58.67 (-0.67)
Merck's Shortened Hep C Regimens Fall Short of Cure-Rate Goal
at The Street - Sun Nov 09, 5:23PM CST
A triple therapy combining two experimental Merck drugs with Gilead's Sovaldi yielded interim hepatitis C cure rates for ranging from 80% to 87% following six to eight weeks of treatment.
GILD: 108.28 (+1.83), MRK: 58.67 (-0.67), ABBV: 63.82 (+2.32)
Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal
PR Newswire - Fri Nov 07, 10:00AM CST
Merck (NYSE: MRK), known as MSD outside the United States and Canada, is teaming with celebrity chef and cookbook author Leticia Moreinos Schwartz on Desafiando La Diabetes: Logra Tus Metas, an educational program encouraging Hispanics with type 2 diabetes to achieve better control of their blood sugar -- a key treatment goal to help reduce the risk of serious health problems. Hispanics in the United States are at a higher risk for developing type 2 diabetes than non-Hispanic white adults, and it is the fifth leading cause of death within the Hispanic community. Chef Leticia, who has a family history of type 2 diabetes, will visit select cities to cook up some of her favorite diabetes-friendly Latin recipes, urge Hispanics to know their A1C (average blood sugar level over the past two to three months), and work with their doctors to set and attain their own A1C goal.
MRK: 58.67 (-0.67)
Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA
PR Newswire - Fri Nov 07, 7:50AM CST
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Amgen, Inc. (NASDAQ: AMGN), Shire PLC (NASDAQ: SHPG) and HCA Holdings Inc. (NYSE: HCA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7775-100free.
HCA: 67.26 (+1.51), JNJ: 108.60 (+0.40), PCYC: 133.44 (-0.05), SHPG: 201.52 (+2.94), MRK: 58.67 (-0.67), AMGN: 162.64 (+2.39)
Global Cell Expansion Market Outlook 2019 - Product, Cell Type, Application & End User Analysis of the $14 Billion Industry
M2 - Fri Nov 07, 6:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/hw245b/cell_expansion) has announced the addition of the "Cell Expansion Market by Product , Cell Type, Application, End User - Forecast to 2019" report to their offering. The global cell expansion market is expected to reach $14.8 billion by 2019 from $6.0 billion in 2014, growing at a CAGR of 19.7% from 2014 to 2019 The global cell expansion market is categorized on the basis of product, cell type, application, end user, and geography. The human cell expansion segment is expected to register the highest growth rate in the cell expansion market, by cell type, during the forecast period. Its favorable growth is attributed to increasing focus on human stem cell research and the increasing usage of stem cell for treating various disorders. Also, the market of regenerative medicines is expected to grow at highest CAGR in the cell expansion application market. This growth is attributed to the increasing government investments and technological advancements in this segment. Major factors contributing to growth of the cell expansion market include the increasing research activities, technological advancements, high prevalence of chronic diseases, and rising investments by companies are likely to propel the growth of this market. Furthermore, government support in the form of funding is another major factor providing impetus for growth of this market. For instance, in April 2013, the Scottish government granted $13.5 million to the College of Life Sciences at the University of Dundee (Scotland) for development of advanced stem cell technology. The relatively untapped markets of the Asian region and advent of 3D technology in cell expansion have opened an array of opportunities for the cell expansion market. However, the high cost of instruments and ethical concerns are expected to restrain the growth of this market. Scope of the Report Product - Reagent - Media - Serum - Bioreactors - Centrifuge Cell Type - Human - Animal Application - Stem Cell Research - Regenerative Medicine - Clinical Diagnostics End User - Hospital - Biotechnology - Cell Bank) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Cell Expansion Market, By Product 8 Cell Expansion Market, By Cell Type 9 Cell Expansion Market, By Application 10 Cell Expansion Market, By End User 11 Cell Expansion Market, By Geography 12 Competitive Landscape 13 Company Profiles - Beckman Coulter (Subsidiary of Danaher Corporation) - Becton Dickinson and Company - Corning Incorporated - Ge Healthcare (A Fully Owned Subsidiary of General Electric Company) - Merck Millipore (A Segment of Merck Kgaa) - Miltenyi Biotec - Sigma-Aldrich Corporation - Stemcell Technologies - Terumo BCT (A Subsidiary of Terumo Corporation) - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/hw..._expansion
GE: 26.47 (+0.06), SIAL: 135.60 (+0.26), MRK: 58.67 (-0.67), DHR: 81.38 (+0.19)
Global Cognitive Impairment Therapeutics Pipeline Review 2014 - 53 Drug Profiles from 23 Leading Pharma Companies
M2 - Fri Nov 07, 6:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/jxpc52/cognitive) has announced the addition of the "Cognitive Impairment - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cognitive Impairment, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cognitive Impairment and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - F. Hoffmann-La Roche Ltd. - AstraZeneca PLC - Merck & Co., Inc. - Panacea Pharmaceuticals, Inc. - Pfizer Inc. - Teva Pharmaceutical Industries Limited - Shire Plc - Evotec AG - Suven Life Sciences Ltd. - AGY Therapeutics, Inc. - Cardax Pharmaceuticals, Inc. - Siena Biotech S.p.A. - Virogenomics, Inc. - Dart NeuroScience LLC - Omeros Corporation - Intra-Cellular Therapies, Inc. - Heptares Therapeutics Ltd. - Pacific Northwest Biotechnology, LLC - Vicore Pharma AB - Pherin Pharmaceuticals, Inc. - AbbVie Inc. - Saniona AB For more information visit http://www.researchandmarkets.com/research/jxpc52/cognitive
SHPG: 201.52 (+2.94), PFE: 30.24 (+0.32), MRK: 58.67 (-0.67), AZN: 73.32 (+0.44), TEVA: 58.21 (+0.51), ITCI: 14.92 (-0.34), ABBV: 63.82 (+2.32), BMY: 58.55 (+0.23), OMER: 17.08 (-0.29)
Dow Jones (DJIA) Today: Merck (MRK) Lower
at The Street - Thu Nov 06, 12:00PM CST
Holding back the Dow today is Merck (NYSE:MRK), which is lagging the broader Dow index with a 33-cent decline (-0.6%) bringing the stock to $59.24.
MRK: 58.67 (-0.67)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab), Merck's Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented for the First Time
Business Wire - Thu Nov 06, 8:08AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that in November and December, data will be presented for the first time investigating the use of KEYTRUDA(R) (pembrolizumab) - the company's anti-PD-1 therapy - in advanced melanoma in comparison to chemotherapy, and in relapsed/refractory classical Hodgkin Lymphoma (cHL) as well as advanced triple negative breast cancer (TNBC). These studies will be presented in oral sessions at the Society for Melanoma Research (SMR) 2014 International Congress, Nov. 13 - 16, the 56th American Society of Hematology (ASH) Annual Meeting, Dec. 6 - 9, and the San Antonio Breast Cancer Symposium (SABCS), Dec. 9 - 13, respectively. By the end of 2014, data on anti-tumor activity of KEYTRUDA as monotherapy will have been presented in seven different tumor types.
MRK: 58.67 (-0.67)
Stock Futures Shed Losses, Rise; Sierra Wireless, Tableau Rocket
at Investor's Business Daily - Thu Nov 06, 7:58AM CST
Stock futures reversed early losses to point firmly higher ahead of Thursday's open. Dow futures sloughed off a 26-point decline and were up 26.5 points. Nasdaq 100 futures backed out of a 10-point loss to trade 4.2 points above fair market value....
TSLA: 242.08 (+1.88), SWIR: 34.70 (+0.80), V: 250.33 (-2.10), AXP: 92.40 (+0.14), MRK: 58.67 (-0.67), DATA: 83.84 (-1.08), CSCO: 25.10 (-0.23)
BIND Therapeutics Reports Third Quarter 2014 Financial Results and Provides Corporate Update
Business Wire - Thu Nov 06, 6:30AM CST
--- Strengthened management and Board including Chief Medical Officer -
MRK: 58.67 (-0.67), BIND: 9.21 (-0.01)
BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin(TM) Nanomedicines for Oncology
Business Wire - Thu Nov 06, 6:25AM CST
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins(TM), today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology. This collaboration will leverage BIND's proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck's preclinical oncology portfolio.
MRK: 58.67 (-0.67), BIND: 9.21 (-0.01)
Jim Cramer's 'Mad Money' Recap: What a Republican Senate Means for Stocks
at The Street - Wed Nov 05, 7:20PM CST
It's bullish news but you can't buy just anything, Cramer says.
ACT: 247.66 (+1.75), LMT: 186.92 (+0.77), XOM: 96.46 (-0.13), ILMN: 189.51 (+3.16), AKS: 6.63 (+0.01), KORS: 69.49 (-0.46), PAYX: 47.54 (+0.21), RIG: 29.43 (-0.28), EOG: 98.98 (-0.57), COST: 137.53 (-0.18), TWTR: 40.00 (-0.31), OXY: 87.87 (-0.17), KO: 42.41 (+0.09), SEAS: 18.53 (+0.14), TMO: 117.06 (+0.46), NUE: 53.74 (-0.44), TRIP: 73.26 (-0.39), DISCA: 32.51 (-0.11), CHUY: 23.04 (+1.02), LB: 76.09 (+0.48), GEO: 41.18 (-0.22), ESV: 40.18 (-1.13), MPC: 93.94 (-0.14), BAX: 70.62 (+0.01), MRK: 58.67 (-0.67), EXPE: 86.10 (+0.99), STI: 39.74 (+0.08)
SANS Institute Announces Healthcare Cyber Security Summit Speaker Line-Up
PR Newswire - Wed Nov 05, 10:02AM CST
The SANS Institute today announced the speaker line-up for its second annual Healthcare Cyber Security Summit in San Francisco on December 3rd. Included among the speaker list are security experts from Aetna, Kaiser Permanente, Merck and Phoenix Children's Hospital.
MRK: 58.67 (-0.67)
Cell Source CEO, Itamar Shimrat on his firm's transition from preclinical to human clinical trials
ACCESSWIRE - Wed Nov 05, 8:02AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Overcoming graft rejection is the main obstacle when it comes to allogeneic stem cell regeneration and organ transplantation. Current treatment includes the use of systemic immunosuppression, which leaves the patient at risk for opportunistic infections. Recent breakthroughs from Cell Source (OTC: CLCS) in Veto Cell technology, which selectively tunes immune response, may change how immunologists treat blood cancers and bone marrow transplants, as well as the process of how organs are repaired and new ones are regenerated.
MRK: 58.68 (-0.66), SHPG: 201.52 (+2.94)
Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps
Business Wire - Wed Nov 05, 7:30AM CST
--Final stage to focus on planned in-field use studies
MRK: 58.68 (-0.66)
Advaxis Submits Investigational New Drug Application for ADXS31-142 (ADXS-PSA) for the Treatment of Metastatic Castration Resistant Prostate Cancer
GlobeNewswire - Wed Nov 05, 6:46AM CST
Advaxis, Inc.(Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, today announced that the Company has submitted an Investigational New Drug application (IND) to the United States Food and Drug Administration (FDA) to conduct the first-in-human study of ADXS31-142 for the treatment of metastatic castration resistant prostate cancer (mCRPC). ADXS31-142 is Advaxis's lead Lm-LLO immunotherapy designed to specifically target prostate-specific antigen (PSA).
ADXS: 2.86 (+0.11), MRK: 58.68 (-0.66)
Will Endocyte (ECYT) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:50PM CST
Endocyte, Inc. (ECYT) has Earnings ESP of 0.00% and a Zacks Rank #2 (Buy).
ACT: 247.66 (+1.75), ECYT: 5.87 (-0.16), MRK: 58.68 (-0.66), HSP: 56.25 (-0.07)
Watch for Shares of Merck (MRK) to Approach Resistance at $59.83
Comtex SmarTrend(R) - Tue Nov 04, 8:58AM CST
Shares of Merck (NYSE:MRK) opened today above their pivot of $58.47 and have already reached the first level of resistance at $59.38. Analysts will be watching for a cross of the next upside pivot targets of $59.83 and $61.19.
MRK: 58.68 (-0.66)
